Connecting healthcare businesses to global markets and capital
NS Nuvantis is a Singapore-based cross-border healthcare platform working across pharmaceutical market access, international commercialization, strategic partnerships and healthcare investment.
About Nuvantis
Building healthcare businesses across borders
Nuvantis sits where manufacturers, distributors, healthcare groups and investors need each other but rarely meet on equal terms.
The healthcare industry increasingly requires capabilities that extend beyond manufacturing. Successful companies need access to international markets, workable regulatory pathways, reliable commercial partners, differentiated products and patient capital.
Manufacturers require access to markets. Distributors require differentiated products. Growing healthcare businesses require strategic capital. Investors require capable local partners who understand both the opportunity and the execution environment.
We identify opportunities, connect complementary organizations and work alongside our partners from initial strategy through commercial execution. Our role is not limited to introductions — we remain involved where we can materially contribute to the outcome.
Selective
We take on opportunities with a clear strategic rationale and where Nuvantis can add measurable value.
Partnership-led
Sustainable healthcare businesses are built through aligned long-term partnerships, not transactional relationships.
Execution-oriented
Our work continues through registration, partner development, negotiation and commercialization.
International
We connect manufacturing capability in emerging markets with commercial and investment opportunity abroad.
What we do
Four platforms, one commercial thesis
Nuvantis combines capabilities that are usually fragmented across different organizations, allowing us to assess an opportunity from both an operating and an investment perspective.
International market access
Helping pharmaceutical manufacturers identify attractive international markets and build sustainable commercial operations in them — market prioritization, portfolio assessment, regulatory pathway planning, partner identification, pricing and launch.
Licensing and business development
In-licensing and out-licensing, manufacturing and contract manufacturing partnerships, technology transfer, commercial representation, distribution agreements, co-development and joint ventures.
Healthcare investment
Investing selectively in healthcare businesses in Bangladesh, and working alongside development finance institutions, private equity funds, strategic investors and family offices seeking exposure to the sector.
Strategic healthcare projects
Developing new manufacturing platforms, specialty healthcare businesses and cross-border ventures from concept through execution, bringing together technical partners, operators and capital.
How we work
From opportunity to execution
Registration is a milestone, not the objective. We stay engaged through the stages where international businesses are usually won or lost.
Most cross-border pharmaceutical relationships end at the point of registration, which is precisely where the commercial work begins. We structure our engagements so that market development remains a shared objective.
For pharmaceutical manufacturers
Turning manufacturing capability into international growth
Strong manufacturing does not automatically translate into successful international business. Expansion requires disciplined market selection, the right products, regulatory planning and capable local partners.
Portfolio strategy
We assess existing and pipeline products to determine where they have genuine international potential.
Market selection
We prioritize markets on regulatory feasibility, commercial opportunity, competition and partner availability.
Regulatory coordination
We structure registration programmes and coordinate local applicants, consultants and commercial partners.
Partner development
We identify and engage distributors, importers and healthcare groups, then manage the relationship.
Commercial negotiation
Pricing, minimum volumes, exclusivity, payment terms and long-term commercial arrangements.
Market development
Once products are registered we support ongoing development rather than ending the relationship.
We work with manufacturers through market-development agreements, product development agreements, licensing, joint ventures or strategic investment. Every structure is built around the specific opportunity.
For distributors and healthcare partners
Access to capable manufacturers and high-potential products
For distributors, hospital groups and healthcare organizations, we identify products and manufacturing partners matched to specific market requirements.
- Branded generic products
- Generic pharmaceuticals
- Specialty pharmaceuticals
- Sterile products
- Oncology products
- Ophthalmic products
- Peptide and metabolic products
- Contract manufacturing
- Private-label products
- Technology partnerships
- Product licensing
We facilitate the full sequence — product identification, manufacturer evaluation, commercial negotiation, regulatory coordination, supply planning and launch — with the objective of building partnerships capable of becoming significant long-term businesses.
Healthcare investment
Investing in the future of healthcare in Bangladesh
Bangladesh combines a large domestic population, an established pharmaceutical manufacturing industry, rising healthcare expenditure and a growing need for long-term growth capital.
Nuvantis identifies healthcare businesses where capital combined with strategic and international capability can accelerate growth. We invest directly and alongside qualified investment partners — development finance institutions, private equity and healthcare-focused funds, strategic corporate investors, sovereign investment organizations, family offices and impact investors.
Pharmaceutical manufacturing
Growth capital, capacity expansion, modernization and export-oriented manufacturing.
Specialty pharmaceuticals
Oncology, sterile injectables, hormones, peptides and other technically differentiated categories.
Pharmaceutical ingredients
API manufacturing, intermediates and other strategic inputs supporting supply-chain resilience.
Hospitals and diagnostics
Selected healthcare delivery platforms with strong operating fundamentals and room to expand.
Healthcare technology
Technology-enabled businesses improving access, efficiency, diagnostics or delivery.
Medical devices
Manufacturing, distribution and technology-transfer opportunities.
What Nuvantis brings to investors
Local origination
Access to healthcare companies and opportunities that are not broadly marketed.
Sector understanding
Commercial and regulatory knowledge of pharmaceutical and healthcare businesses.
Transaction development
Support in evaluating, structuring and developing investment opportunities.
Post-investment participation
Continued involvement to support growth initiatives and international commercialization.
Markets
A deliberately selective market strategy
We do not believe pharmaceutical companies need to enter every market. Thin coverage of many markets is more expensive and less durable than a strong position in a few.
Southeast Asia
Building pharmaceutical partnerships across ASEAN and neighbouring markets.
Middle East and GCC
Licensing, distribution and healthcare investment opportunities across the Gulf and wider region.
Africa
High-growth markets where access to quality, affordable medicines remains a priority.
South Asia
Regional proximity and manufacturing capability applied to cross-border partnerships.
We enter a market when products have genuine competitive potential, the regulatory pathway is achievable, credible local partners can be identified, the commercial economics are sustainable, and the manufacturer can build a lasting position.
Therapeutic and product areas
Weighted towards differentiated categories
We work across the pharmaceutical sector while maintaining particular interest in higher-value products where capability, not price alone, decides the outcome.
Conventional pharmaceuticals
Oral solid, liquid and other conventional dosage forms with strong market potential.
Specialty pharmaceuticals
Products requiring specialized commercial, regulatory or manufacturing capability.
Oncology
Oral and injectable oncology products and related manufacturing platforms.
Sterile injectables
Complex injectables requiring advanced manufacturing and quality systems.
Ophthalmology
Sterile ophthalmic products and related specialty portfolios.
Peptides and metabolic therapies
Emerging peptide-based therapies and related manufacturing opportunities.
APIs and ingredients
Strategic inputs supporting supply-chain resilience and manufacturing competitiveness.
Partnership model
Flexible structures, long-term alignment
Different opportunities require different forms of partnership, so we take a deliberately flexible approach to commercial and investment structures.
Commercial representation
Representing manufacturers in selected international markets.
Revenue-sharing partnerships
Building export businesses alongside manufacturers through aligned structures.
Licensing
Structuring product or technology licensing agreements across markets.
Joint ventures
Creating new businesses with manufacturing, commercial or investment partners.
Strategic investment
Taking equity positions in selected healthcare companies or projects.
Project development
Assembling technical partners, operators, investors and commercial partners around new platforms.
What we look for in partners
- Strong management
- Quality-focused operations
- Long-term thinking
- Transparency
- International ambition
- Commercial discipline
Insights
Perspectives on healthcare and international markets
Selected views on the developments shaping pharmaceutical manufacturing, market access and healthcare investment.
Bangladesh pharmaceuticals after LDC graduation: building the next export model
Graduation changes which products can be exported and on what terms. The manufacturers that prepare their portfolios and registrations now will define the sector's next decade.
Why manufacturers need a market-led export strategy
Export businesses built around whatever the plant already makes tend to stall. Starting from market demand and working back to the portfolio produces a materially different result.
The opportunity in specialty pharmaceutical manufacturing
Oncology, sterile injectables and peptides demand capability that few emerging-market manufacturers have built — which is exactly why the margins remain defensible.
Healthcare investment in Bangladesh: where institutional capital can create value
The sector's constraint is rarely capital alone. It is the combination of capital with commercial capability and international market access.
Partner with us
Build with Nuvantis
We welcome conversations with companies and investors developing healthcare businesses across borders.
Pharmaceutical manufacturers
Developing international markets or identifying licensing opportunities.
Distributors and healthcare companies
Seeking products, manufacturing partners or strategic collaborations.
Investors
Evaluating healthcare investment opportunities in Bangladesh.
Strategic partners
Developing a healthcare platform, joint venture or new manufacturing project.
NS Nuvantis Pte Ltd · Singapore
srahman@nsnuvantis.com